Celldex Therapeutics (CLDX) Competitors $18.37 +0.58 (+3.26%) Closing price 04:00 PM EasternExtended Trading$18.38 +0.01 (+0.05%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CLDX vs. FOLD, LGND, DVAX, MNKD, BCRX, INVA, NVAX, OPK, GERN, and MYGNShould you be buying Celldex Therapeutics stock or one of its competitors? The main competitors of Celldex Therapeutics include Amicus Therapeutics (FOLD), Ligand Pharmaceuticals (LGND), Dynavax Technologies (DVAX), MannKind (MNKD), BioCryst Pharmaceuticals (BCRX), Innoviva (INVA), Novavax (NVAX), OPKO Health (OPK), Geron (GERN), and Myriad Genetics (MYGN). These companies are all part of the "biotechnology" industry. Celldex Therapeutics vs. Amicus Therapeutics Ligand Pharmaceuticals Dynavax Technologies MannKind BioCryst Pharmaceuticals Innoviva Novavax OPKO Health Geron Myriad Genetics Celldex Therapeutics (NASDAQ:CLDX) and Amicus Therapeutics (NASDAQ:FOLD) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, community ranking, media sentiment, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership. Does the MarketBeat Community believe in CLDX or FOLD? Celldex Therapeutics received 91 more outperform votes than Amicus Therapeutics when rated by MarketBeat users. Likewise, 75.24% of users gave Celldex Therapeutics an outperform vote while only 72.98% of users gave Amicus Therapeutics an outperform vote. CompanyUnderperformOutperformCelldex TherapeuticsOutperform Votes62375.24% Underperform Votes20524.76% Amicus TherapeuticsOutperform Votes53272.98% Underperform Votes19727.02% Do analysts rate CLDX or FOLD? Celldex Therapeutics presently has a consensus price target of $54.33, indicating a potential upside of 198.04%. Amicus Therapeutics has a consensus price target of $16.75, indicating a potential upside of 144.17%. Given Celldex Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Celldex Therapeutics is more favorable than Amicus Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Celldex Therapeutics 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.89Amicus Therapeutics 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.78 Does the media refer more to CLDX or FOLD? In the previous week, Amicus Therapeutics had 7 more articles in the media than Celldex Therapeutics. MarketBeat recorded 11 mentions for Amicus Therapeutics and 4 mentions for Celldex Therapeutics. Amicus Therapeutics' average media sentiment score of 1.00 beat Celldex Therapeutics' score of 0.72 indicating that Amicus Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Celldex Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Amicus Therapeutics 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, CLDX or FOLD? Celldex Therapeutics has a beta of 1.59, meaning that its stock price is 59% more volatile than the S&P 500. Comparatively, Amicus Therapeutics has a beta of 0.79, meaning that its stock price is 21% less volatile than the S&P 500. Is CLDX or FOLD more profitable? Amicus Therapeutics has a net margin of -10.62% compared to Celldex Therapeutics' net margin of -1,544.32%. Amicus Therapeutics' return on equity of 12.44% beat Celldex Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Celldex Therapeutics-1,544.32% -19.75% -18.86% Amicus Therapeutics -10.62%12.44%2.60% Which has preferable valuation and earnings, CLDX or FOLD? Celldex Therapeutics has higher earnings, but lower revenue than Amicus Therapeutics. Amicus Therapeutics is trading at a lower price-to-earnings ratio than Celldex Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCelldex Therapeutics$7.02M172.39-$141.43M-$2.45-7.44Amicus Therapeutics$528.30M3.99-$151.58M-$0.18-38.11 SummaryCelldex Therapeutics beats Amicus Therapeutics on 9 of the 17 factors compared between the two stocks. Remove Ads Get Celldex Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CLDX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CLDX vs. The Competition Export to ExcelMetricCelldex TherapeuticsDiagnostic substances IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.21B$2.31B$5.34B$7.60BDividend YieldN/A0.78%5.11%4.33%P/E Ratio-7.096.0921.7617.83Price / Sales172.3947.61378.0693.28Price / CashN/A15.7538.1534.64Price / Book2.012.946.414.00Net Income-$141.43M-$65.73M$3.20B$247.23M7 Day Performance20.49%9.28%6.59%7.42%1 Month Performance-10.72%-14.79%-8.57%-6.15%1 Year Performance-53.34%-18.68%10.11%-0.03% Celldex Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CLDXCelldex Therapeutics2.3254 of 5 stars$18.37+3.3%$54.33+195.8%-54.7%$1.22B$7.02M-7.15150Positive NewsFOLDAmicus Therapeutics4.0285 of 5 stars$7.15-4.7%$16.75+134.3%-37.1%$2.20B$528.30M-39.72480Positive NewsGap DownLGNDLigand Pharmaceuticals4.3435 of 5 stars$99.41-0.2%$147.00+47.9%+31.0%$1.91B$167.13M39.6180Analyst UpgradeNews CoveragePositive NewsGap DownDVAXDynavax Technologies4.3787 of 5 stars$12.49-1.3%$21.50+72.1%-3.4%$1.55B$277.25M69.39350Positive NewsGap DownMNKDMannKind2.2584 of 5 stars$4.69-1.1%$9.21+96.5%+11.6%$1.43B$285.50M67.00400BCRXBioCryst Pharmaceuticals4.1287 of 5 stars$6.79-0.6%$15.57+129.3%+47.6%$1.42B$450.71M-11.13530Gap DownINVAInnoviva4.3495 of 5 stars$17.51-1.2%$55.00+214.1%+22.9%$1.10B$358.71M25.38100Analyst UpgradeNews CoveragePositive NewsNVAXNovavax3.6164 of 5 stars$6.54+4.8%$18.00+175.2%+49.8%$1.05B$682.16M-2.891,990OPKOPKO Health4.1159 of 5 stars$1.53-1.3%$2.75+79.7%+15.4%$1.03B$713.14M-8.053,930Options VolumeGERNGeron3.7691 of 5 stars$1.41+2.2%$5.75+307.8%-63.7%$898.04M$76.99M-4.4170Short Interest ↑Gap DownMYGNMyriad Genetics3.823 of 5 stars$8.07-0.7%$20.89+158.9%-58.7%$736.86M$837.60M-6.212,700Gap Down Remove Ads Related Companies and Tools Related Companies Amicus Therapeutics Alternatives Ligand Pharmaceuticals Alternatives Dynavax Technologies Alternatives MannKind Alternatives BioCryst Pharmaceuticals Alternatives Innoviva Alternatives Novavax Alternatives OPKO Health Alternatives Geron Alternatives Myriad Genetics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CLDX) was last updated on 4/15/2025 by MarketBeat.com Staff From Our PartnersGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredDOGE tax surpriseElon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax auth...Altimetry | SponsoredAmazon ShockerJeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...Stansberry Research | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Celldex Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Celldex Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CLDX Stock Free CLDX Stock Alerts